Otsuka extended collaboration on digital medicines with Proteus Digital Health

Otsuka Pharmaceutical and Proteus Digital Health announce the signing of an expanded global collaboration agreement that will strengthen the relationship between the two companies for the further development and commercialization of a portfolio of medicines including the ABILIFY MYCITE® (aripiprazole tablets with sensor) offering, which received NDA approval from the U.S. Food and Drug Administration in November 2017.

This arrangement reinforces both companies’ continued commitment to provide new advancements in digital medicine products and care models to address the needs of patients suffering from severe mental illness.  As part of the expanded collaboration, Otsuka made $88 million in related equity and other payments to Proteus.  The expanded agreement covers the development and commercialization of digital medicines over the next five years.

A collaborative team comprised of Otsuka and Proteus employees will be dedicated to commercial development and market coordination for the ABILIFY MYCITE System, software integration and standardization, manufacturing and supply chain integration, and coordination. This includes the joint development of an expanded portfolio of digital medicines consisting of other therapies such as atypical antipsychotics used in the treatment of serious mental illness integrated with Proteus sensors.  The parties will also work on the joint development of next generation product features and sensor capabilities to expand the potential of digital medicine offerings.

Otsuka Pharmaceutical (Japan), a global healthcare company,  researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health. Otsuka is a leader in the challenging area of mental health and has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue.

Proteus Digital Health is enabling a new category of pharmaceuticals: Digital Medicines. These include widely used drugs, formulated so they communicate when they have been ingested; a wearable patch that detects medicines and captures physiologic response; mobile applications to support patient self-care and physician decision-making; and data analytics to serve the needs of health system managers. The company has more than 450 issued patents that protect this enabling technology, and regulatory clearances in the U.S., European Union and China.

SOURCE: proteus
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.